‘Including patients in clinical trials is critical in developing new innovative treatments and, ultimately, in improving the nation’s health’ Dr Rebecca Cramp, Director of Code and Regulatory Affairs, IPHA.
- IPHA HSE CRO model Clinical Trial Agreement May 2024
- Explanation-for-the-May 2024 tripartite CROmodel-Clinical-Trial-Agreement-for-use-in-all-interventional-clinical-trials-in-Ireland
- IPHA Clinical Trials Activity Comparison Report 2024
- IPHA Clinical Trials Activity Comparison Report 2024_Infographic_Making Ireland a European Leader
- IPHA & HSE model Clinical Trial Agreement August 2024
- Explanation-for-the-Aug 2024 model-Clinical-Trial-Agreement-for-use-in-all-interventional-clinical-trials-in-Ireland
- IPHA Clinical Trial Compensation Guidelines February 2023
- HSE’s National Office data protection tool for Transfer Impact Assessments
- Data Protection Impact Assessment responsibilities in clinical trials_06Dec2024
Superseded
Background
There is clear published evidence that by including patients in clinical trials their health improves substantially. We believe that Ireland can play a leading role in the provision of clinical trials in Europe. To do that, it is essential that we have a predictable, transparent and efficient clinical research system to compete internationally and to attract clinical trials. Healthcare providers in Irish hospitals and academic institutions have shown that they have the ability to participate and drive world-class research. IPHA has collaborated with the State Claims Agency and HSE in the creation of the standard Clinical Trial Indemnity Form and model Clinical Trial Agreement, respectively, which have substantially improved the start-up efficiency of clinical trials. We are continuing to work hard to remove other barriers, create a better environment for the conduct of clinical trials in Ireland and ensure that Irish patients can access key life-changing trials in Ireland.
For further details please contact info@ipha.ie.